vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $75.5M, roughly 1.5× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 9.0%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
BY vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $75.5M |
| Net Profit | $37.6M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 33.4% | — |
| Revenue YoY | 9.0% | 27.7% |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | $0.83 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $75.5M | ||
| Q3 25 | $115.7M | $54.5M | ||
| Q2 25 | $110.5M | $52.4M | ||
| Q1 25 | $103.1M | $46.0M | ||
| Q4 24 | $104.7M | $59.1M | ||
| Q3 24 | $101.8M | $80.5M | ||
| Q2 24 | $99.4M | $47.1M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $8.8M | ||
| Q2 25 | $30.1M | $5.9M | ||
| Q1 25 | $28.2M | $3.0M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $20.3M | ||
| Q2 24 | $29.7M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 22.7% | ||
| Q3 25 | 43.1% | 17.6% | ||
| Q2 25 | 35.2% | 12.7% | ||
| Q1 25 | 36.4% | 8.7% | ||
| Q4 24 | 38.6% | 22.6% | ||
| Q3 24 | 39.3% | 27.4% | ||
| Q2 24 | 40.4% | -4.6% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | 16.2% | ||
| Q2 25 | 27.2% | 11.2% | ||
| Q1 25 | 27.4% | 6.5% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | 25.2% | ||
| Q2 24 | 29.9% | -9.6% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.26 | ||
| Q3 25 | $0.82 | $0.17 | ||
| Q2 25 | $0.66 | $0.12 | ||
| Q1 25 | $0.64 | $0.06 | ||
| Q4 24 | $0.68 | $0.40 | ||
| Q3 24 | $0.69 | $0.41 | ||
| Q2 24 | $0.68 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.3B | $130.3M |
| Total Assets | $9.9B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $97.5M | ||
| Q3 25 | $259.0M | $94.4M | ||
| Q2 25 | $218.3M | $96.0M | ||
| Q1 25 | $421.3M | $93.2M | ||
| Q4 24 | $563.1M | $101.0M | ||
| Q3 24 | $452.6M | $96.7M | ||
| Q2 24 | $730.5M | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $130.3M | ||
| Q3 25 | $1.2B | $115.3M | ||
| Q2 25 | $1.2B | $104.7M | ||
| Q1 25 | $1.1B | $97.1M | ||
| Q4 24 | $1.1B | $92.1M | ||
| Q3 24 | $1.1B | $71.1M | ||
| Q2 24 | $1.0B | $48.5M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $216.3M | ||
| Q3 25 | $9.8B | $202.9M | ||
| Q2 25 | $9.7B | $194.9M | ||
| Q1 25 | $9.6B | $196.2M | ||
| Q4 24 | $9.5B | $213.3M | ||
| Q3 24 | $9.4B | $220.7M | ||
| Q2 24 | $9.6B | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $14.4M | ||
| Q3 25 | $38.3M | $9.7M | ||
| Q2 25 | $16.3M | $14.1M | ||
| Q1 25 | $27.1M | $3.6M | ||
| Q4 24 | $175.2M | $15.6M | ||
| Q3 24 | $19.8M | $11.0M | ||
| Q2 24 | $40.1M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $14.4M | ||
| Q3 25 | $38.0M | $9.7M | ||
| Q2 25 | $15.2M | $14.1M | ||
| Q1 25 | $25.0M | $3.6M | ||
| Q4 24 | $171.2M | $15.6M | ||
| Q3 24 | $19.1M | $11.0M | ||
| Q2 24 | $39.4M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 19.1% | ||
| Q3 25 | 32.8% | 17.7% | ||
| Q2 25 | 13.7% | 26.8% | ||
| Q1 25 | 24.3% | 7.7% | ||
| Q4 24 | 163.5% | 26.4% | ||
| Q3 24 | 18.8% | 13.7% | ||
| Q2 24 | 39.7% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 2.0% | 0.1% | ||
| Q4 24 | 3.8% | 0.0% | ||
| Q3 24 | 0.6% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | 1.10× | ||
| Q2 25 | 0.54× | 2.41× | ||
| Q1 25 | 0.96× | 1.21× | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | 0.54× | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
